TS TITLE Click here for the Fast Money Trade School Lesson of the week. |
The Fast Money five takes a look at the week's biggest market movers. | |||
Text to Talk Daily Alerts | Trades you won't find on TV | Fast Money Podcasts Want to go Face 2 Face with the Fast Money Five? Email the fast money team at |
As I wrote in this column last week: it always stops raining. And with a major assist from the Fed, the most volatile week in nearly 60 years came to a close with the Dow halting a four-week losing streak to eke out a small gain. If you have the stomach to handle these turbulent markets, money-making opportunities abound. And in the end, that's all you can ask for. But past is prologue, and it is always with an eye on the future that we look to make Fast Money. And there is perhaps no better week to try to do just that than next week. A virtual orgy of economic and earnings data will hit the tape, from a crucial Fed meeting on Tuesday and Wednesday, to GDP on Wednesday as well, and ultimately the Jobs Report on Friday. Some have accused Fed Chief Ben Bernanke of being both early and late when he made a surprise three-quarters of a percent rate cut this week. But the markets staged an extraordinary rebound following the move. How many more bullets does the nation's top Money Man have left in his gun? And to what extent will Bernanke's actions (or non-actions) during the Fed meeting be validated or invalidated by the Jobs Report on Friday? All crucial questions that the Fast Money will be watching. Also on the Fast Money radar: a deluge of earnings from companies in nearly every sector. Tech names like Amazon, Google and Yahoo will surely light up trading screens. We saw this week how hyper-growth names like Apple can fall out of bed with even a whiff of weakness. On the other hand, a mature tech name, Microsoft, posted some of its best results in years. Could we start to see a rotation out of the standout names of '07 and into the more established, slower-growing names? Call them "value Tech". Tech will share the spotlight with Big Pharma names next week too. Merck, Wyeth, and Bristol-Myers are all set to report. With the election heating up and interest rates dropping, drug stocks, with their healthy dividends, may warrant more attention. Lest we forget, there's also a bevy of Dow components reporting. 3M, Altria, Verizon, Boeing and Procter & Gamble are all out with results next week, providing a snapshot of the American economy, and certainly, more money-making opportunities. A busy week indeed, my friends, making Fast Money required viewing in what promises to be one crazy week. Remember, an open market is one in which you can make money. And we will try to do just that all next week. I'll see you then.. If you have questions about The Final Trade or suggestions for Fast Money, please send an email to FastMoney@cnbc.com |
All opinions expressed by the Program Participants are solely their current opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them. Such opinions are based upon information they consider reliable, but neither CNBC nor its affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. The Program Participants are professional traders who may be actively involved in securities discussed herein, on behalf of themselves, their companies and their clients. Also, the opinions expressed by the Program Participants may be short-term in nature and are subject to change. No part of the Program Participants' compensation from CNBC is related to the specific opinions they express. Past performance is not indicative of future results. Neither the Program Participants nor CNBC guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed herein. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned herein may not be suitable for you and you should make your own independent decision regarding them. This material does not take into account your particular investment objectives, financial situation or needs and is not intended as recommendations appropriate for you. You should strongly consider seeking advice from your own investment adviser. To unsubscribe from The Final Trade click here |